FDA panel shakes off J&J's hopes of broader Xarelto use

A panel of FDA advisers voted 10-0 against recommending that Johnson & Johnson's ($JNJ) Xarelto be approved to treat patients with acute coronary syndrome, marking the third such rejection for the treatment. The drug is already indicated for atrial fibrillation among other ailments, but J&J has long had its heart set on the sizable market for ACS therapies. Article

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.